ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för belinostat. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

17 träffar

Bibliografisk träff 2015-01-21

Paclitaxel/carboplatin with or without belinostat as empiric first-line treatment for patients with carcinoma of unknown primary site: A randomized, phase 2 trial.

Hainsworth JD, Daugaard G, Lesimple T, Hübner G, Greco FA, Stahl MJ, Büschenfelde CM, Allouache D, Penel N, Knoblauch P, Fizazi KS.

Cancer · clinical trial, phase ii; research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1002/cncr.29229

Bibliografisk träff 2014-12-09

A phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced myeloid neoplasia.

Odenike O, Halpern A, Godley LA, Madzo J, Karrison T, Green M, Fulton N, Mattison RJ, Yee KW, Bennett M, Koval G, Malnassy G, Larson RA, Ratain MJ, Stock W.

Invest New Drugs · research support, non-u.s. gov't; research-article; multicenter study; clinical trial, phase i; randomized controlled trial; journal article; research support, n.i.h., extramural · DOI 10.1007/s10637-014-0194-2

Bibliografisk träff 2014-12-01

Drug monographs: belinostat and idelalisib.

Piper WL, Waddell JA, Solimando DA.

Hosp Pharm · research-article; journal article · DOI 10.1310/hpj4911-1009

Bibliografisk träff 2014-11-27

Combination treatment of renal cell carcinoma with belinostat and 5-fluorouracil: a role for oxidative stress induced DNA damage and HSP90 regulated thymidine synthase.

Kim MJ, Lee JS, Park SE, Yi HJ, Jeong IG, Kang JS, Yun J, Lee JY, Ro S, Lee JS, Choi EK, Hwang JJ, Kim CS.

J Urol · research support, non-u.s. gov't; journal article · DOI 10.1016/j.juro.2014.11.091

Bibliografisk träff 2014-11-24

PXD101 significantly improves nuclear reprogramming and the in vitro developmental competence of porcine SCNT embryos.

Jin JX, Kang JD, Li S, Jin L, Zhu HY, Guo Q, Gao QS, Yan CG, Yin XJ.

Biochem Biophys Res Commun · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bbrc.2014.11.051

Bibliografisk träff 2014-11-17

A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma.

Foss F, Advani R, Duvic M, Hymes KB, Intragumtornchai T, Lekhakula A, Shpilberg O, Lerner A, Belt RJ, Jacobsen ED, Laurent G, Ben-Yehuda D, Beylot-Barry M, Hillen U, Knoblauch P, Bhat G, Chawla S, Allen LF, Pohlman B.

Br J Haematol · clinical trial, phase ii; multicenter study; journal article · DOI 10.1111/bjh.13222

Bibliografisk träff 2014-11-12

Novel heat shock protein 90 inhibitor NVP-AUY922 synergizes with the histone deacetylase inhibitor PXD101 in induction of death of anaplastic thyroid carcinoma cells.

Kim SH, Kang JG, Kim CS, Ihm SH, Choi MG, Yoo HJ, Lee SJ.

J Clin Endocrinol Metab · research support, non-u.s. gov't; journal article · DOI 10.1210/jc.2014-3101

Bibliografisk träff 2014-10-24

Profile of belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma.

Bodiford A, Bodge M, Talbott MS, Reddy NM.

Onco Targets Ther · review-article; review; journal article · DOI 10.2147/ott.s59269

Bibliografisk träff 2014-09-04

A phase I/II trial of belinostat in combination with cisplatin, doxorubicin, and cyclophosphamide in thymic epithelial tumors: a clinical and translational study.

Thomas A, Rajan A, Szabo E, Tomita Y, Carter CA, Scepura B, Lopez-Chavez A, Lee MJ, Redon CE, Frosch A, Peer CJ, Chen Y, Piekarz R, Steinberg SM, Trepel JB, Figg WD, Schrump DS, Giaccone G.

Clin Cancer Res · clinical trial, phase ii; research support, n.i.h., intramural; research-article; clinical trial, phase i; journal article · DOI 10.1158/1078-0432.ccr-14-0968

Bibliografisk träff 2014-09-01

Epigenetic and molecular mechanisms underlying the antileukemic activity of the histone deacetylase inhibitor belinostat in human acute promyelocytic leukemia cells.

Savickiene J, Treigyte G, Valiuliene G, Stirblyte I, Navakauskiene R.

Anticancer Drugs · research support, non-u.s. gov't; journal article · DOI 10.1097/cad.0000000000000122

Bibliografisk träff 2014-09-01

Belinostat: first global approval.

Poole RM.

Drugs · journal article · DOI 10.1007/s40265-014-0275-8

Bibliografisk träff 2014-05-01

Belinostat for the treatment of peripheral T-cell lymphomas.

McDermott J, Jimeno A.

Drugs Today (Barc) · review; journal article · DOI 10.1358/dot.2014.50.5.2138703

Bibliografisk träff 2014-02-24

A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium Study.

Kirschbaum MH, Foon KA, Frankel P, Ruel C, Pulone B, Tuscano JM, Newman EM.

Leuk Lymphoma · clinical trial, phase ii; research-article; journal article; research support, n.i.h., extramural · DOI 10.3109/10428194.2013.877134

Bibliografisk träff 2013-09-10

Long-term complete remission with belinostat in a patient with chemotherapy refractory peripheral T-cell lymphoma.

Reimer P, Chawla S.

J Hematol Oncol · journal article; case reports; case-report · DOI 10.1186/1756-8722-6-69

Bibliografisk träff 2013-04-09

LC-MS/MS assay for the quantitation of the HDAC inhibitor belinostat and five major metabolites in human plasma.

Kiesel BF, Parise RA, Tjørnelund J, Christensen MK, Loza E, Tawbi H, Chu E, Kummar S, Beumer JH.

J Pharm Biomed Anal · research support, non-u.s. gov't; research-article; validation study; journal article; research support, n.i.h., extramural · DOI 10.1016/j.jpba.2013.03.025

Bibliografisk träff 2013-03-08

Growth inhibition of pancreatic cancer cells by histone deacetylase inhibitor belinostat through suppression of multiple pathways including HIF, NFkB, and mTOR signaling in vitro and in vivo.

Chien W, Lee DH, Zheng Y, Wuensche P, Alvarez R, Wen DL, Aribi AM, Thean SM, Doan NB, Said JW, Koeffler HP.

Mol Carcinog · research-article; journal article · DOI 10.1002/mc.22024

Bibliografisk träff 2013-01-30

Glucuronidation by UGT1A1 is the dominant pathway of the metabolic disposition of belinostat in liver cancer patients.

Wang LZ, Ramírez J, Yeo W, Chan MY, Thuya WL, Lau JY, Wan SC, Wong AL, Zee YK, Lim R, Lee SC, Ho PC, Lee HS, Chan A, Ansher S, Ratain MJ, Goh BC.

PLoS One · research support, non-u.s. gov't; research-article; multicenter study; clinical trial, phase i; journal article · DOI 10.1371/journal.pone.0054522